Dr. Postow Discusses Combination Therapy for Melanoma

Video

In Partnership With:

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination therapy for patients with melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses combination therapy for patients with melanoma.

There are many new combination therapies for patients with melanoma, says Postow. In the BRAF-mutant population, there are combinations of BRAF and MEK inhibitors with immunotherapy drugs that are moving into phase III trials.

Immunotherapy combinations are also moving forward in clinical trials as well, adds Postow. Namely, combinations of IDO blockers and PD-1 agents.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,